A Phase 2 interventional study of OPC 131461 10mg group and OPC 131461 5mg group in Cardiac Edema (CHF), sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Heart Failure · Otsuka Holdings Co., Ltd..
Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 2, and was the 15th registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →None of the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. is open now. The open studies under Heart Failure, anywhere →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
This study's enrollment of 157 is above the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 81 across the 16 interventional studies, 1,600 across the 1 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the dose response in respect of weight decrease following repeated oral administration of OPC-131461 at 1, 2, 5, and 10 mg or placebo in patients with CHF with volume overload despite having received diuretics other than vasopressin antagonists
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects undergoing any of the following diuretic therapies
Exclusion Criteria:
OPC-131461 5 mg tablet x 2
Drug: OPC 131461 10mg group
OPC-131461 5 mg tablet and placebo tablet
Drug: OPC 131461 5mg group
OPC-131461 1 mg tablet x 2
Drug: OPC 131461 2mg group
OPC-131461 1 mg tablet and placebo tablet
Drug: OPC 131461 1mg group
Placebo tablet
Drug: Placebo
OPC-131461 5 mg tablet x 2,once-daily oral administration for 14 days
OPC-131461 5 mg tablet and placebo tablet,once-daily oral administration for 14 days
OPC-131461 1 mg tablet x 2,once-daily oral administration for 14 days
OPC-131461 1 mg tablet and placebo tablet,once-daily oral administration for 14 days
Placebo tablet,once-daily oral administration for 14 days
Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8
Calculate the change in body weight from the baseline up to Day 8 (kg)
Time frame: Baseline, Day 8
Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 15
Calculate the percentage change in body weight from the baseline up to last assessment time point (the day after IMP administration) by Day 15 (%)
Time frame: Baseline, Day15
Improvement of or Change in Congestive Findings ( Lower Limb Edema ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7
The tibial margins or acrotarsia in a sitting position will be examined to assess the severity of edema according to the criteria in 0 : Absent, No pitting observed at all, 1:Mild,Slight pitting observed, 2:Moderate, Pitting observed, 3 : Severe,Apparent edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.
Time frame: Baseline, Day7
Improvement of or Change in Congestive Findings ( Pulmonary Congestion ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7
The severity of pulmonary congestion will be determined according to the criteria in 0 : Absent, No congestion, 1:Mild,Pulmonary venous congestion, 2:Moderate, Interstitial pulmonary edema, 3 : Severe, Alveolar pulmonary edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.
Time frame: Baseline, Day7
| Milestone | Material A | Material B | Material C | Material D | Placebo |
|---|---|---|---|---|---|
| Started | 31 | 32 | 31 | 33 | 30 |
| Completed | 27 | 28 | 22 | 29 | 25 |
| Not completed | 4 | 4 | 9 | 4 | 5 |
| Withdrew: Adverse event | 0 | 4 | 4 | 3 | 1 |
| Withdrew: Physician decision | 2 | 0 | 4 | 1 | 3 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
Calculate the change in body weight from the baseline up to Day 8 (kg)
| kg | Material A | Material B | Material C | Material D | Placebo |
|---|---|---|---|---|---|
| Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8 | -1.96 (-2.50 to -1.42) | -1.74 (-2.28 to -1.20) | -1.4 (-1.94 to -0.85) | -1.84 (-2.36 to -1.31) | -1.17 (-1.72 to -0.62) |
Calculate the percentage change in body weight from the baseline up to last assessment time point (the day after IMP administration) by Day 15 (%)
| kg | Material A | Material B | Material C | Material D | Placebo |
|---|---|---|---|---|---|
| Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 15 | -2.12 (-2.80 to -1.44) | -2.11 (-2.79 to -1.43) | -1.72 (-2.41 to -1.03) | -1.87 (-2.53 to -1.21) | -1.38 (-2.07 to -0.69) |
The tibial margins or acrotarsia in a sitting position will be examined to assess the severity of edema according to the criteria in 0 : Absent, No pitting observed at all, 1:Mild,Slight pitting observed, 2:Moderate, Pitting observed, 3 : Severe,Apparent edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.
| Participants | Material A | Material B | Material C | Material D | Placebo |
|---|---|---|---|---|---|
| Improvement of or Change in Congestive Findings ( Lower Limb Edema ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7 | 16 | 18 | 9 | 19 | 19 |
The severity of pulmonary congestion will be determined according to the criteria in 0 : Absent, No congestion, 1:Mild,Pulmonary venous congestion, 2:Moderate, Interstitial pulmonary edema, 3 : Severe, Alveolar pulmonary edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.
| Participants | Material A | Material B | Material C | Material D | Placebo |
|---|---|---|---|---|---|
| Improvement of or Change in Congestive Findings ( Pulmonary Congestion ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7 | 21 | 19 | 10 | 22 | 18 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 10 - 14 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Material A | 0/31 (0%) | 0/31 (0%) | 11/31 (35.5%) |
| Material B | 0/32 (0%) | 2/32 (6.3%) | 8/32 (25%) |
| Material C | 0/31 (0%) | 0/31 (0%) | 12/31 (38.7%) |
| Material D | 1/33 (3%) | 1/33 (3%) | 14/33 (42.4%) |
| Placebo | 1/30 (3.3%) | 1/30 (3.3%) | 8/30 (26.7%) |
| Event | Material A | Material B | Material C | Material D | Placebo |
|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/31 | 0/32 | 0/31 | 0/33 | 1/30 |
| HypernatraemiaMetabolism and nutrition disorders | 0/31 | 0/32 | 0/31 | 0/33 | 1/30 |
| Cerebral infarctionNervous system disorders | 0/31 | 0/32 | 0/31 | 0/33 | 1/30 |
| Angina pectorisCardiac disorders | 0/31 | 1/32 | 0/31 | 0/33 | 0/30 |
| ChondrocalcinosisMusculoskeletal and connective tissue disorders | 0/31 | 1/32 | 0/31 | 0/33 | 0/30 |
| ArrhythmiaCardiac disorders | 0/31 | 0/32 | 0/31 | 1/33 | 0/30 |
| Event | Material A | Material B | Material C | Material D | Placebo |
|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 0/31 | 2/32 | 5/31 | 1/33 | 0/30 |
| ConstipationGastrointestinal disorders | 2/31 | 2/32 | 4/31 | 3/33 | 2/30 |
| ThirstGeneral disorders | 4/31 | 4/32 | 0/31 | 4/33 | 0/30 |
| COVID-19Infections and infestations | 0/31 | 0/32 | 0/31 | 0/33 | 3/30 |
| DehydrationMetabolism and nutrition disorders | 3/31 | 1/32 | 1/31 | 2/33 | 0/30 |
| NasopharyngitisInfections and infestations | 0/31 | 0/32 | 0/31 | 1/33 | 2/30 |
| HypotensionVascular disorders | 1/31 | 1/32 | 2/31 | 1/33 | 2/30 |
| Dry mouthGastrointestinal disorders | 2/31 | 0/32 | 1/31 | 1/33 | 0/30 |
| Blood pressure decreasedInvestigations | 2/31 | 0/32 | 0/31 | 0/33 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 0/31 | 1/32 | 1/31 | 2/33 | 1/30 |
Safety analysis set, which included all randomized patients who received ≥1 dose of the study medication.
| Age, Categorical(Participants) | Material A | Material B | Material C | Material D | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 5 | 3 | 3 | 5 | 22 |
| >=65 years | 25 | 27 | 28 | 30 | 25 | 135 |
| Age, Continuous(Years) | Material A | Material B | Material C | Material D | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 73.5 ± 11.6 | 75.2 ± 10.7 | 75.3 ± 13.1 | 76.7 ± 7.9 | 76.4 ± 9.4 | 75.4 ± 10.6 |
| Sex: Female, Male(Participants) | Material A | Material B | Material C | Material D | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 19 | 2 | 11 | 12 | 58 |
| Male | 17 | 13 | 29 | 22 | 18 | 99 |
| Race (NIH/OMB)(Participants) | Material A | Material B | Material C | Material D | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 31 | 32 | 31 | 33 | 30 | 157 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Jan 2023 to primary completion in Oct 2024, 21 months.
Results were first posted in Oct 2025, 11 months after primary completion.
Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 21 months is close to that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Co., Ltd. →